StemCells, Inc. (NASDAQ:STEM)

CAPS Rating: 2 out of 5

A biopharmaceutical company that operates in one segment, the development of novel cell-based therapeutics designed to treat human diseases and disorders.

Recs

0
Player Avatar bshope (56.11) Submitted: 3/28/2011 3:39:06 PM : Outperform Start Price: $8.60 STEM Score: -92.62

Their upcoming clinical trials will be a big news story.

Featured Broker Partners


Advertisement